There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...
In a first for the consumer health wearables category, Google has introduced a feature on its Pixel Watch and Fitbit Air devices that it says can monitor insulin resistance using passive sensors, ...
US cost-effectiveness watchdog ICER has concluded that AstraZeneca's first-in-class aldosterone synthase inhibitor (ASI) Baxfendy for resistant hypertension does not offer value for money. In a ...
Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...
A therapy room used to deliver the one-off, therapist-assisted treatment. Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in ...
Lilly has filed six new lawsuits – naming US companies Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide as defendants – alleging they are selling ...
Insmed is joining forces with an organisation representing people living with the chronic lung disorder bronchiectasis to carry out a large-scale, real-world study of its recently approved therapy ...
AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...
A kidney transplant patient with a rare, multidrug-resistant (MDR) infection has become the first to be treated using an adjunctive bacteriophage therapy developed by Denmark's SNIPR Biome. The ...
The central challenge facing modern health systems is no longer lifespan alone. It is the widening gap between how long people live and how long they remain healthy, independent, and functional.
Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...
The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results